What the human research shows
One good phase 2 with a large effect and a distinctive side-effect profile. Grade C for stage: a single trial of 263 people, however well run, is not a phase 3 programme.
Evidence profile0–5
- Metabolic & weightC2.0
- Cardiovascular—0.0
- Muscle & growth—0.0
- Healing & repair—0.0
- Neuro & sleep—0.0
- Immune & inflammation—0.0
- Sexual & hormonal—0.0
- Skin & appearance—0.0
- Ageing & longevity—0.0
| Outcome | Grade | Effect size | Human studies | Where the evidence comes from |
|---|---|---|---|---|
| Body weight | CWeak | Large | 1 phase 2 RCT (n=263, 48 wk) | Six dose regimens against placebo in adults with obesity and no diabetes. Loss ranged from 9% at 1 mg to 20% at 9 mg; placebo lost 0.4%. Efficacy estimand, so participants who stopped are not fully counted.1 |
| Body weight (with tirzepatide, type 2 diabetes) | CWeak | Large | 1 phase 2b RCT topline (n=367, 48 wk) | Lilly press release, 30 September 2026, presented at the EASD meeting: in adults with obesity or overweight and type 2 diabetes, eloralintide 9 mg with tirzepatide 15 mg produced 23.3% weight loss at 48 weeks against 14.8% on tirzepatide 15 mg alone and 3.0% on placebo; HbA1c fell 2.9, 2.4 and 0.3 points. Eloralintide alone reached 12.3%. Read with care: 367 people across ten groups, an efficacy estimand, and 10.8–27.0% of the combination groups stopped for adverse events against 2.9% on tirzepatide alone. Not peer-reviewed.3 |
| Nausea and fatigueadverse | CWeak | Moderate | Same RCT | Nausea reached 64% at the 6 mg fixed dose and was lower with escalation. Fatigue in up to 46% — a side effect the GLP-1 drugs do not produce at that rate, and one to watch in phase 3.1 |
Literature searched to 7 October 2026. Human studies only; animal and cell work informs the mechanism section and nothing else.
Registered trials
ClinicalTrials.gov lists 18 interventional studies naming Eloralintide as an intervention — 3 completed, 11 recruiting, and 1 with results posted to the registry.
A registration is not a result. Anyone can register a study, and many never report — so this list shows what has been attempted, not what has been shown. The graded evidence above is the answer to whether something works.
10 further studies are registered. Participant counts marked * are the sponsor's estimate, not a final enrolment. Source: ClinicalTrials.gov, read directly from the registry and refreshed weekly.
What it is
Amylin is released from the pancreas alongside insulin and tells the brain a meal is over. Eloralintide is a long-acting synthetic agonist of the amylin receptor, built to be selective for it rather than for the closely related calcitonin receptor. It is Lilly's answer to Novo Nordisk's cagrilintide.
It is being developed both alone and in combination with tirzepatide. The published trial is monotherapy; the combination, which Lilly calls EloraTZP, has a phase 2b result in a press release, and Lilly says phase 3 trials of a co-formulated product will start by the end of 2026.
How it is thought to work
Amylin receptors in the hindbrain slow gastric emptying and reduce meal size. Activating them without touching GLP-1 receptors is the test of whether amylin alone can match the incretin drugs; the phase 2 suggests it can, with a different side-effect mix.
What is still unknown
- Whether 20% holds in phase 3 with full accounting for dropouts.
- What the fatigue signal is and whether it limits dosing.
- How it compares with cagrilintide, which has never been tested against it.
The molecule and how long it lasts
- Formula
- C201H319N49O65S2
- Molecular weight
- 4526 g/mol
- CAS number
- 2883634-40-8
- PubChem
- CID 175663130
PubChem record, read 23 September 2026.
- Route
- Subcutaneous, once weekly
- Half-life
- Dose-proportional exposure at steady state reported; no half-life figure in the abstract
From a published human pharmacokinetic study: Bhattachar S, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: phase 1 proof of concept. Diabetes Obes Metab 2026
Regulatory status
Investigational.
Investigational; phase 3 running. Products sold under the name are not the trial drug.
No MHRA licence.
Investigational only.
No Drug Identification Number.
Unapproved anywhere, so S0 (non-approved substances).
Questions people actually ask
Is eloralintide a GLP-1 drug?
How does it compare with cagrilintide?
When will it be approved?
One page per claimed effect
- CDoes Eloralintide help with body weight?1 phase 2 RCT (n=263, 48 wk)
- CDoes Eloralintide help with body weight?1 phase 2b RCT topline (n=367, 48 wk)
- CHow common is nausea and fatigue with Eloralintide?Same RCT
References
- 1Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.Lancet, 2025263 randomised, 46 US centres. NCT06230523.
- 2
- 3Eli Lilly. EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes.Press release, 30 Sep 2026Phase 2b, 367 randomised, 48 weeks, US and Argentina. Efficacy estimand; not peer-reviewed. NCT06603571.
Change log
- 2026-10-07Phase 2b combination result with tirzepatide (press release, 30 Sep 2026) added as a new row, graded C: one small unpublished trial. Overall grade unchanged.
- 2026-09-23Initial publication from the Lancet phase 2. Grade C for stage.